-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $35

Benzinga·06/10/2026 18:34:14
Listen to the news
Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $35.